PVI
INBX

Pura Vida Investments’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Pura Vida Investments’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-93,575
Closed -$2.31M – 205
2022
Q4 		$2.31M Buy
+93,575
New +$2.75M 0.12% 120

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Pura Vida Investments's INBX Position: Q1 2023 in Review

Pura Vida Investments sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2023, closing a stake of 93,575 shares — an estimated $2.31M sold.

Pura Vida Investments first reported a position in INBX in Q4 2022 and held it in 1 quarter. The position peaked at $2.31M in Q4 2022. 108 funds tracked by Wall St. Rank hold INBX as of Q1 2023.

  • Pura Vida Investments reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 93,575 Inhibrx, Inc. Common Stock shares in Q1 2023, an estimated $2.31M.
  • Pura Vida Investments first reported a position in Inhibrx, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Pura Vida Investments's Inhibrx, Inc. Common Stock position peaked at $2.31M in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.